Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claims 1-46 (Canceled)

Claim 47 (Amended) A compound represented by Formula I:



I

or a pharmaceutically acceptable salt or solvate thereof, wherein:

A and B may be taken separately or together;

when taken separately,

A represents halo, C_{1-6}alkyl, OC_{1-6}alkyl or phenyl, said alkyl, phenyl and the alkyl portion of OC_{1-6}alkyl being optionally substituted with 1-3 halo groups; and

B represents represents H, halo, C_{1-6}alkyl, -OC_{1-6}alkyl, -SC_{1-6}alkyl, C_{2-6}alkenyl, phenyl or naphthyl, said alkyl, alkenyl, phenyl, naphthyl, and the alkyl portions of -OC_{1-6}alkyl and -SC_{1-6}alkyl being optionally substituted with 1-3 groups selected from halo, OH, CH_3O, CF_3 and OCF_3; and

when taken together,

A and B together represents (a) C_{1-4}alkylene optionally substituted with 1-3 halo groups, and 1-2 R^a groups wherein R^a represents C_{1-3}alkyl, OC_{1-3}alkyl, $C_{6-10}arC_{1-6}$alkylene or phenyl optionally substituted with 1-3 halo groups, or (b) C_{2-5}alkanediyl such that they form a 3-6 membered ring with the carbon atom to which they are attached, said ring optionally containing 1 double bond or 1-2 heteroatoms selected from O, S and N, said 3-6 membered ring being optionally substituted with C_{1-4}alkylene, oxo, ethylenedioxy or propylenedioxy, and being further optionally substituted with 1-4 groups selected from halo, C_{1-4}alkyl, haloC_{1-4}alkyl, C_{1-3}acyl, C_{1-3}acyloxy, C_{1-3}alkoxy, C_{1-6}alkylOC(O)-, C_{2-4}alkenyl, C_{2-4}alkynyl, C_{1-3}alkoxyC_{1-3}alkyl, C_{1-3}alkoxyC_{1-3}alkoxy, phenyl, CN, OH, D, NH_2, NHR^a and $N(R^a)_2$ wherein R^a is as previously defined;

each R^1 represents H or is independently selected from the group consisting of: OH, halo,

C_{1-10}alkyl, C_{1-6}alkoxy and C_{6-10}aryl, said C_{1-10}alkyl, C_{6-10}aryl and the alkyl portion of C_{1-6}alkoxy being optionally substituted with 1-3 halo, OH, OC_{1-3}alkyl, phenyl or naphthyl groups, said phenyl and naphthyl being optionally substituted with 1-3 substituents independently selected from halo, OCH_3, OCF_3, CH_3, CF_3 and phenyl, wherein said phenyl is optionally substituted with 1-3 halo groups,

or two R^1 groups taken together represent a fused C_{5-6}alkyl or aryl ring, which may be optionally substituted with 1-2 OH or R^a groups, wherein R^a is as defined above;

R^2 and R^3 are taken together ~~or separately~~; and

~~when taken together, R^2 and R^3~~ represent (a) a C_{3-8} alkanediyl forming a fused 5-10 membered non-aromatic ring optionally interrupted with 1-2 double bonds, and optionally containing 1-2 heteroatoms selected from O, S and N; or (b) a fused 6-10 membered aromatic monocyclic or bicyclic group, said alkanediyl and aromatic monocyclic or bicyclic group being optionally substituted with 1-6 halo atoms, and 1-4 of OH, C_{1-3}alkyl, OC_{1-3}alkyl, haloC_{1-3}alkyl, haloC_{1-3}alkoxy, and phenyl, said phenyl being optionally substituted with 1-4 groups independently selected from halo, C_{1-3}alkyl, OC_{1-3}alkyl , and said C_{1-3}alkyl and the C_{1-3}alkyl portion of OC_{1-3}alkyl being optionally substituted with 1-3 halo groups;

~~when taken separately,~~

~~R^2 is selected from the group consisting of: (a) C_{1-14}alkyl optionally substituted with 1-6 halo groups and 1-3 substituents selected from OH, OC_{1-3}alkyl, and phenyl, said phenyl being optionally substituted with 1-4 groups independently selected from halo, OCH_3, OCF_3, CH_3 and CF_3, and said C_{1-3}alkyl portion of OC_{1-3}alkyl being optionally substituted with 1-3 halo groups; (b) phenyl or pyridyl optionally substituted with 1-3 halo, OH or R^a groups, with R^a as previously defined; (c) C_{2-10} alkenyl, optionally substituted with 1-3 substituents independently selected from halo, OH and OC_{1-3}alkyl, said C_{1-3}alkyl portion of OC_{1-3}alkyl being optionally substituted with 1-3 halo groups; (d) CH_2CO_2H; (e) $CH_2CO_2C_{1-6}$alkyl; (f) $CH_2C(O)NHR^a$ wherein R^a is as previously defined; (g) NH_2, NHR^a and $N(R^a)_2$ wherein R^a is as previously defined;~~

~~and R^3 is selected from the group consisting of: C_{1-14}alkyl, C_{2-10}alkenyl, SC_{1-6}alkyl, C_{6-10}aryl, heterocyclyl and heteroaryl, said alkyl, alkenyl, aryl, heterocyclyl, heteroaryl and the alkyl portion of SC_{1-6}alkyl being optionally substituted with (a) R; (b) 1-6 halo groups and (c) 1-3 groups selected from OH, NH_2, NHC_{1-4}alkyl, $N(C_{1-4}alkyl)_2$, C_{1-4}alkyl, OC_{1-4}alkyl, CN, C_{1-4}alkyl$S(O)_x$- wherein x is 0, 1 or 2, C_{1-4}alkylSO_2NH-, H_2NSO_2-, C_{1-4}alkyl$NHSO_2$- and $(C_{1-4}alkyl)_2NSO_2$-, said C_{1-4}alkyl and the C_{1-4}alkyl portions of said groups being optionally substituted with phenyl and 1-3 halo groups,~~ and

R is selected from heterocyclyl, heteroaryl and aryl, said group being optionally substituted with 1-4 groups selected from halo, C_{1-4}alkyl, C_{1-4}alkyl$S(O)_x$-, with x as previously defined, C_{1-4} alkylSO_2NH-, H_2NSO_2-, C_{1-4}alkyl$NHSO_2$-, $(C_{1-4}$ alkyl$)_2NSO_2$-, CN, OH, OC_{1-4}alkyl , and, said C_{1-4}alkyl and the C_{1-4}alkyl portions of said groups being optionally substituted with 1-5 halo and 1 group selected from OH and OC_{1-3}alkyl.

Claim 48 (previously presented) The compound of Claim 47 wherein A and B are taken separately and each represents a C_{1-6}alkyl group, optionally substituted with 1-3 halo groups.

Claim 48 (previously presented) The compound of Claim 47 wherein A and B are taken separately and each represents a C_{1-6}alkyl group, optionally substituted with 1-3 halo groups.

Claim 49 (previously presented) The compound of Claim 47 wherein two R^1 groups represent H and one R^1 is selected from the group consisting of: OH, halo, C_{1-10}alkyl, C_{1-6}alkoxy and C_{6-10}aryl, said C_{1-10}alkyl, C_{6-10}aryl and the alkyl portion of C_{1-6}alkoxy being optionally substituted with 1-3 halo, OH, OC_{1-3}alkyl, phenyl or naphthyl groups, said phenyl and naphthyl being optionally substituted with 1-3 substituents selected from: halo, OCH_3, OCF_3, CH_3, CF_3 and phenyl, wherein said phenyl is optionally substituted with 1-3 halo groups.

Claim 50 (previously presented) The compound of Claim 47 wherein one R^1 group represents H and two R^1groups are selected from the group consisting of: OH, halo, C_{1-10}alkyl and C_{1-6}alkoxy, said C_{1-10}alkyl and the alkyl portion of C_{1-6}alkoxy being optionally substituted with 1-3 halo groups.

Claim 51 (previously presented) The compound of Claim 50 wherein two R^1 groups represent halo or methyl.

Claim 52-57 (Cancelled)

Claim 58 (previously presented) The compound of Claim 47 wherein R^2 and R^3 are taken together and represent: (a) a C_{3-8} alkanediyl forming a fused 5-10 membered non-aromatic ring optionally interrupted with 1 double bond, and optionally interrupted by 1 heteroatom selected from O, S and N; or (b) a fused 6-10 membered aromatic monocyclic or bicyclic group, said alkanediyl and aromatic monocyclic or bicyclic group being optionally substituted with 1-3 halo atoms, and 1-2 of OH, C_{1-3}alkyl, OC_{1-3}alkyl, haloC_{1-3}alkyl, haloC_{1-3}alkoxy and phenyl, said phenyl being optionally substituted with 1-2 groups independently selected from halo, C_{1-3}alkyl, OC_{1-3}alkyl , and said C_{1-3}alkyl and the C_{1-3}alkyl portion of OC_{1-3}alkyl being optionally substituted with 1-3 halo groups.

Claim 59 (previously presented) The compound of Claim 47 wherein R is selected from heterocyclyl, heteroaryl and aryl, said group being optionally substituted with 1-4 halo groups and 1-2 groups selected from C_{1-4}alkyl, C_{1-4}alkyl$S(O)_x$-, wherein x is 0, 1 or 2, C_{1-4} alkylSO_2NH-, H_2NSO_2-, C_{1-4}alkyl$NHSO_2$-, $(C_{1-4}$ alkyl$)_2NSO_2$-, CN, OH and OC_{1-4}alkyl, said C_{1-4}alkyl and the C_{1-4}alkyl portions of said groups being optionally substituted with 1-3 halo groups and 1 group selected from OH and

OC_{1-3}alkyl.

Claim 60 (previously presented) The compound of Claim 47 selected from the table set forth below:

		
		
		

		
		
		
		
		

		
		
		
		
		



or a pharmaceutically acceptable salt or solvate thereof.

Claim 61 (previously presented) A pharmaceutical composition comprising a compound in accordance with Claim 47 in combination with a pharmaceutically acceptable carrier.

Claim 62 (previously presented) A method of treating hyperglycemia, diabetes or insulin resistance in a mammalian patient in need of such treatment which comprises administering to said patient an effective amount of a compound in accordance with Claim 47.

Claim 63 (previously presented) A method of treating non-insulin dependent diabetes mellitus in a mammalian patient in need of such treatment comprising administering to the patient an anti-diabetic effective amount of a compound in accordance with Claim 47.

Claim 64 (previously presented) A method of treating obesity in a mammalian patient in need of such treatment compriseing administering to said patient a compound in accordance with Claim 47 in an amount that is effective to treat obesity.

Claim 65 (previously presented) A method of treating Syndrome X in a mammalian patient in need of such treatment, comprising administering to said patient a compound in accordance with Claim 47 in an amount that is effective to treat Syndrome X.

Claim 66 (previously presented) A method of treating a lipid disorder selected from the group conisting of dyslipidemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, low HDL and high LDL in a mammalian patient in need of such treatment, comprising administering to said patient a compound in accordance with Claim 47 in an amount that is effective to treat said lipid disorder.

Claim 67 (previously presented) A method of treating atherosclerosis in a mammalian patient in need of such treatment, comprising administering to said patient a compound in accordance with Claim 47 in an amount effective to treat atherosclerosis.